Tilray (NASDAQ:TLRY - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $213.38 million for the quarter. Tilray has set its FY 2025 guidance at EPS.
Tilray (NASDAQ:TLRY - Get Free Report) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The firm had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. Tilray's quarterly revenue was up 8.7% compared to the same quarter last year. On average, analysts expect Tilray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Tilray Trading Down 0.4 %
Shares of TLRY traded down $0.00 during mid-day trading on Wednesday, reaching $0.65. 9,635,705 shares of the company's stock traded hands, compared to its average volume of 41,587,836. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. The stock's 50-day moving average is $0.83 and its two-hundred day moving average is $1.25. Tilray has a 12 month low of $0.58 and a 12 month high of $2.97. The stock has a market cap of $610.79 million, a P/E ratio of -2.17 and a beta of 2.13.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group upped their price objective on Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $2.70.
Check Out Our Latest Stock Analysis on Tilray
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Further Reading
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
